Urologikum Lübeck

Industry / private company


Location: Lübeck, Germany (DE) DE

ISNI: -

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Prognostic potential of baseline HRQoL in advanced and metastatic renal cell carcinoma (2022) Gruenwald V, Goebell P, Schostak M, Welslau M, Doehn C, Degenkolbe E, Ehness R, et al. Conference contribution The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape (2022) Doehn C, Bögemann M, Grünwald V, Welslau M, Bedke J, Schostak M, Wolf T, et al. Journal article Molecular tumor board—renal cell carcinoma Molekulares Tumorboard – Nierenzellkarzinom (2019) Grünwald V, Doehn C, Goebell P Journal article, Review article Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study (2019) Goebell P, Hermann E, Kube U, Doehn C, Marschner N, Dietel A, Blumenstengel K, et al. Journal article Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL (2018) Boegemann M, Bedke J, Schostak M, Welslau M, Hering-Schubert C, Wolf T, Schleicher J, et al. Conference contribution Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study (2017) Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, et al. Conference contribution Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape (2017) Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, et al. Conference contribution Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study (2015) Bergmann L, Kube U, Doehn C, Steiner T, Goebell P, Kindler M, Herrmann E, et al. Journal article